2013
DOI: 10.1186/1745-6673-8-28
|View full text |Cite
|
Sign up to set email alerts
|

Expression of VPAC1 in a murine model of allergic asthma

Abstract: Vasoactive intestinal polypeptide (VIP) is a putative neurotransmitter of the inhibitory non-adrenergic non-cholinergic nervous system and influences the mammalian airway function in various ways. Hence known for bronchodilatory, immunomodulatory and mucus secretion modulating effects by interacting with the VIP receptors VPAC1 and VPAC2, it is discussed to be a promising target for pharmaceutical intervention in common diseases such as COPD and bronchial asthma. Here we examined the expression and transcripti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 23 publications
0
2
0
Order By: Relevance
“…VIP mediates its functions through two G proteincoupled receptors, the VIP-pituitary adenylate cyclase ac- tivating peptide receptors, VPAC1 and VPAC2 [49] . In humans and murine models the increased expression of VPAC1 in the airways of chronic bronchitis smokers, in the alveolar macrophages of COPD patients and in allergic asthma was reported [50][51][52] . This increased expression of VIP receptors may indicate that the ligand is missing, that the ligand is not active or that the signaling of the receptors is not correctly mediated.…”
Section: Discussionmentioning
confidence: 97%
“…VIP mediates its functions through two G proteincoupled receptors, the VIP-pituitary adenylate cyclase ac- tivating peptide receptors, VPAC1 and VPAC2 [49] . In humans and murine models the increased expression of VPAC1 in the airways of chronic bronchitis smokers, in the alveolar macrophages of COPD patients and in allergic asthma was reported [50][51][52] . This increased expression of VIP receptors may indicate that the ligand is missing, that the ligand is not active or that the signaling of the receptors is not correctly mediated.…”
Section: Discussionmentioning
confidence: 97%
“…VIP mediates its functions through two G protein-coupled receptors, the VIP-pituitary adenylate cyclase activating peptide receptors, VPAC1 and VPAC2 [49]. In humans and murine models the increased expression of VPAC1 in the airways of chronic bronchitis smokers, in the alveolar macrophages of COPD patients and in allergic asthma was reported [50,51,52]. This increased expression of VIP receptors may indicate that the ligand is missing, that the ligand is not active or that the signaling of the receptors is not correctly mediated.…”
Section: Discussionmentioning
confidence: 99%